Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC).
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Participate on Nov. 9 in National Lung Cancer Screening Day
The American College of Radiology® (ACR®) is partnering with the American Cancer Society National Lung Cancer Roundtable, the Radiology Health Equity Coalition and Go2 for Lung Cancer on National Lung Cancer Screening Day.
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer.
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the [Food and Drug Administration had approved Optune Lua](
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Novocure stock rocketed late Tuesday after the FDA signed off on its treatment for patients with metastatic lung cancer.
Novocure Shares Rise After FDA Approves Optune Lua Cancer Treatment
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer.
Novocure gets FDA approval for its lung cancer treatment
Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.
For people with lung cancer, exercise can be grueling, but evidence of benefits is growing
When you think of lung cancer treatment, what comes to mind—chemotherapy, radiation, surgery? While these can be crucial, ...
Becker's Hospital Review7h
Is lung cancer screening the industry's next 'business win'?
Timothy Mullett, MD, leaned toward his computer screen as he spoke, drowning out the sounds of the busy coffee shop behind him to get his message across.
Delaware has 15th highest cancer death rate in US, new data shows
The report shows that Delaware has above-average rates of deaths for two specific cancers. Here's what you need to know.
For people with lung cancer, exercise can be gruelling. It’s also among the most important things
Research shows regular physical activity can significantly improve quality of life for lung cancer patients. This includes ...
EurekAlert!1d
Long-lasting immunotherapy response in stage IV lung cancer with brain metastasis
A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response ...
The Meadville Tribune2d
Lung cancer screenings save lives, but most people don’t know about them
A significant weapon in the fight against lung cancer may be going to waste, as a survey revealed most Americans aren’t aware ...
MedPage Today7d
ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?
The changes were based on an analysis of data from the Cancer Intervention and Surveillance Modeling Network that estimated ...
Carilion encourages people to get screening for lung cancer
ROANOKE, Va. (WDBJ) - National lung cancer screening day is Saturday, Nov. 9, and Carilion is scheduling appointments for ...
FierceBiotech12h
BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...